Publications
Chosen filters:
Chosen filters:
Evaluation of host genetic and viral factors as surrogate markers for HTLV-1-associated myelopathy/tropical spastic paraparesis in Peruvian HTLV-1-infected patients Institute of Tropical Medicine
The role of non-viral load surrogate markers in HIV-positive patient monitoring during antiviral treatment Institute of Tropical Medicine
A closed-form estimator for meta-analysis and surrogate markers evaluation Hasselt University KU Leuven
Estimating complex linear mixed models using an iterative full maximum likelihood estimator can be cumbersome in some cases. With small and unbalanced datasets, convergence problems are common. Also, for large datasets, iterative procedures can be computationally prohibitive. To overcome these computational issues, an unbiased two-stage closed-form estimator for the multivariate linear mixed model is proposed. It is rooted in ...
Evaluation of HIV-1 p24 antigenemia and level of CD8+CD38+ T cells as surrogate markers of HIV-1 RNA viral load in HIV-1-infected patients in Dakar Institute of Tropical Medicine
Surrogate markers predicting overall survival for lung cancer University of Antwerp
The present systematic review was performed under the auspices of the European Lung Cancer Working Party (ELCWP) in order to determine the role of early intermediate criteria (surrogate markers) in determining treatment efficacy instead of survival in patients with lung cancer. Preliminarily, the level of evidence for the use of overall survival to evaluate treatment efficacy was reviewed. Nine questions were then formulated by the ELCWP. After ...
Statistical Validation of Surrogate Markers in Clinical Trials Hasselt University
The increasing cost of drug development has raised the demand on the use of biomarkers as surrogate endpoints for the evaluation of new drugs in clinical trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation process has proven challenging for conceptual and practical reasons. In ...
Statistical validation of surrogate markers in clinical trials KU Leuven
© 2014 Springer-Verlag Berlin Heidelberg. All rights are reserved. The increasing cost of drug development has raised the demand on the use of biomarkers as surrogate endpoints for the evaluation of new drugs in clinical trials. However, failed past attempts to use surrogate endpoints made it clear that, before deciding on the use of a candidate surrogate endpoint, it is of the utmost importance to investigate its validity. Such validation ...
Identification of differentially methylated BRCA1 and CRISP2 DNA regions as blood surrogate markers for cardiovascular disease University of Antwerp
Genome-wide Illumina InfiniumMethylation 450 K DNA methylation analysis was performed on blood samples from clinical atherosclerosis patients (n=8) and healthy donors (n=8) in the LVAD study (NCT02174133, NCT01799005). Multiple differentially methylated regions (DMR) could be identified in atherosclerosis patients, related to epigenetic control of cell adhesion, chemotaxis, cytoskeletal reorganisations, cell proliferation, cell death, estrogen ...
Independent associations of total and high molecular weight adiponectin with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with rheumatoid arthritis Vrije Universiteit Brussel
INTRODUCTION: Whether adiponectin levels associate with atherogenesis in RA is uncertain. We examined the independent relationships of total and high molecular weight (HMW) adiponectin concentrations with cardiometabolic risk and surrogate markers of enhanced early atherogenesis in black and white patients with RA.
METHODS: We determined total and HMW adiponectin concentrations and those of endothelial activation molecules including ...